Form 4: Sutro Biopharma Executive Gerber Reports Stock Transactions
SEC Form 4 Filing
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On March 1, 2025, Hans-Peter Gerber, the Chief Scientific Officer of Sutro Biopharma, had 11,250 restricted stock units (RSUs) vest.
- Following the vesting, 4,621 shares were withheld by the issuer to cover income tax obligations at a price of $1.59 per share.
- After these transactions, Gerber directly owns 30,749 shares of common stock and 33,750 restricted stock units.
- The RSUs vest annually, with 1/4th of the total award vesting each year beginning March 1, 2025, contingent upon continued service.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by an executive, with no inherently positive or negative implications.
Future Outlook
The RSUs vest annually, with 1/4th of the total award vesting each year beginning March 1, 2025, contingent upon continued service.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors regarding the trading activities of company executives.
Stakeholder Impact
- Shareholders gain insight into executive compensation and stock ownership.
- Employees may be impacted by the company's overall financial health and stock performance.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of earliest transaction, vesting of RSUs, and tax withholding. |
| 03/01/2025 | RSUs vest as to 1/4th of the total award annually beginning on this date. |
| 03/01/2028 | Expiration date of the Restricted Stock Units. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.